Topline Results of the KHK4951 Phase 2 study in nAMD patients September 9 th , 2026 Chief Medical Officer (CMO) Yoshifumi Torii Kyowa Kirin Co., Ltd. NCT06116890 This document contains forward-looking statements regarding the outlook, targets, plans, and other future-related matters of the Company (including its consolidated subsidiaries in Japan and overseas). These statements are based on our reasonable judgments using current information and forecasts but involve uncertainties that could cause actual res ...